Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite.

Rena Nishizawa, Toshihiko Nishiyama, Katsuya Hisaichi, Naoki Matsunaga, Chiaki Minamoto, Hiromu Habashita, Yoshikazu Takaoka, Masaaki Toda, Shiro Shibayama, Hideaki Tada, Kenji Sagawa, Daikichi Fukushima, Kenji Maeda, Hiroaki Mitsuya

文献索引：Bioorg. Med. Chem. Lett. 17(3) , 727-31, (2007)

全文：HTML全文

摘要

Hydroxylated derivatives were designed and synthesized based on the information of oxidative metabolites. Compounds derived from beta-substituted (2R,3R)-2-amino-3-hydroxypropionic acid showed improved inhibitory activities against the binding of MIP-1alpha to human CCR5, compared with the non-hydroxylated derivatives and the other isomers.